Sumoylation of HDAC2 promotes NF-κB-dependent gene expression

Oncotarget

Volumn 6, Issue 9, 2015, Pages 7123-7135

  Wagner, Tobias ^a   Kiweler, Nicole ^b   Wolff, Katharina ^a   Knauer, Shirley K ^c   Brandl, André ^a   Hemmerich, Peter ^d   Dannenberg, Jan Hermen ^e   Heinzel, Thorsten ^a   Schneider, Günter ^f   Krämer, Oliver H ^b  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^c UNIVERSITY OF DUISBURG ESSEN   (Germany)

^d FRITZ LIPMANN INSTITUTE   (Germany)

^e NETHERLANDS CANCER INSTITUTE   (Netherlands)

^f TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Histone deacetylase 2; P53; P65; RSK1; SUMO

Indexed keywords

DOXORUBICIN; HISTONE DEACETYLASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN P53; RIBOSOMAL S6 KINASE 1; S6 KINASE; SURVIVIN; UNCLASSIFIED DRUG; HDAC2 PROTEIN, HUMAN; MUTAGENIC AGENT; TP53 PROTEIN, HUMAN;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER RESISTANCE; CATALYSIS; CELL PROTECTION; CELL STRESS; CELL SURVIVAL; COLON CANCER; CONTROLLED STUDY; DNA BINDING; EMBRYO; GENE EXPRESSION REGULATION; GENOTOXICITY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; SUMOYLATION; WILD TYPE; ANIMAL; CELL NUCLEUS; CHEMISTRY; COLON TUMOR; FIBROBLAST; GENE EXPRESSION PROFILING; GENETICS; HEK293 CELL LINE; HOMEOSTASIS; METABOLISM; REPORTER GENE; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; CATALYSIS; CELL LINE, TUMOR; CELL NUCLEUS; COLONIC NEOPLASMS; FIBROBLASTS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, REPORTER; HEK293 CELLS; HISTONE DEACETYLASE 2; HOMEOSTASIS; HUMANS; MICE; MUTAGENS; NF-KAPPA B; SIGNAL TRANSDUCTION; SUMOYLATION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84927145208     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3344     Document Type: Article

References (58)

1. Oeckinghaus A, Hayden MS, Ghosh S. Crosstalk in NF-kappaB signaling pathways. Nature immunology. 2011; 12: 695-708.
2. Hayden MS, Ghosh S. NF-kappaB, the first quarter-century: remarkable progress and outstanding questions. Genes & development. 2012; 26: 203-234.
3. Staudt LM. Oncogenic activation of NF-kappaB. Cold Spring Harbor perspectives in biology. 2010; 2: a000109.
4. Schneider G, Krämer OH. NFkappaB/p53 crosstalk-a promising new therapeutic target. Biochim Biophys Acta. 2011; 1815: 90-103.
5. McCool KW, Miyamoto S. DNA damage-dependent NF-kappaB activation: NEMO turns nuclear signaling inside out. Immunological reviews. 2012; 246: 311-326.
6. Moreno R, Sobotzik JM, Schultz C, Schmitz ML. Specification of the NF-kappaB transcriptional response by p65 phosphorylation and TNF-induced nuclear translocation of IKK epsilon. Nucleic acids research. 2010; 38: 6029-6044.
7. Roos WP, Kaina B. DNA damage-induced cell death: from specific DNA lesions to the DNA damage response and apoptosis. Cancer Lett. 2013; 332: 237-248.
8. Wu ZH, Wong ET, Shi Y, Niu J, Chen Z, Miyamoto S, Tergaonkar V. ATM-and NEMO-dependent ELKS ubiquitination coordinates TAK1-mediated IKK activation in response to genotoxic stress. Molecular cell. 2010; 40: 75-86.
9. Schneider G, Henrich A, Greiner G, Wolf V, Lovas A, Wieczorek M, Wagner T, Reichardt S, von Werder A, Schmid RM, Weih F, Heinzel T, Saur D, Krämer OH. Cross talk between stimulated NF-kappaB and the tumor suppressor p53. Oncogene. 2010; 29: 2795-2806.
10. Johnson RF, Perkins ND. Nuclear factor-kappaB, p53, and mitochondria: regulation of cellular metabolism and the Warburg effect. Trends in biochemical sciences. 2012; 37: 317-324.
11. Ryan KM, Ernst MK, Rice NR, Vousden KH. Role of NF-kappaB in p53-mediated programmed cell death. Nature. 2000; 404: 892-897.
12. Bohuslav J, Chen LF, Kwon H, Mu Y, Greene WC. p53 induces NF-kappaB activation by an IkappaB kinase-independent mechanism involving phosphorylation of p65 by ribosomal S6 kinase 1. The Journal of biological chemistry. 2004; 279: 26115-26125.
13. Frank AK, Leu JI, Zhou Y, Devarajan K, Nedelko T, Klein-Szanto A, Hollstein M, Murphy ME. The codon 72 polymorphism of p53 regulates interaction with NF-{kappa}B and transactivation of genes involved in immunity and inflammation. Molecular and cellular biology. 2011; 31: 1201-1213.
14. Yang XJ, Seto E. The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men. Nature reviews. Molecular cell biology. 2008; 9: 206-218.
15. Kelly RD, Cowley SM. The physiological roles of histone deacetylase (HDAC) 1 and 2: complex co-stars with multiple leading parts. Biochemical Society transactions. 2013; 41: 741-749.
16. Spange S, Wagner T, Heinzel T, Krämer OH. Acetylation of non-histone proteins modulates cellular signalling at multiple levels. Int J Biochem Cell Biol. 2009; 41: 185-198.
17. Brandl A, Heinzel T, Krämer OH. Histone deacetylases: salesmen and customers in the post-translational modification market. Biology of the cell / under the auspices of the European Cell Biology Organization. 2009; 101: 193-205.
18. Ouyang J, Gill G. SUMO engages multiple corepressors to regulate chromatin structure and transcription. Epigenetics : official journal of the DNA Methylation Society. 2009; 4: 440-444.
19. Brandl A, Wagner T, Uhlig KM, Knauer SK, Stauber RH, Melchior F, Schneider G, Heinzel T, Krämer OH. Dynamically regulated sumoylation of HDAC2 controls p53 deacetylation and restricts apoptosis following genotoxic stress. J Mol Cell Biol. 2012; 4: 284-293.
20. Citro S, Jaffray E, Hay RT, Seiser C, Chiocca S. A role for paralog-specific sumoylation in histone deacetylase 1 stability. J Mol Cell Biol. 2013; 5: 416-427.
21. Hickey CM, Wilson NR, Hochstrasser M. Function and regulation of SUMO proteases. Nature reviews. Molecular cell biology. 2012; 13: 755-766.
22. Geiss-Friedlander R, Melchior F. Concepts in sumoylation: a decade on. Nature reviews. Molecular cell biology. 2007; 8: 947-956.
23. Wagner T, Brand P, Heinzel T, Krämer OH. Histone deacetylase 2 controls p53 and is a critical factor in tumorigenesis. Biochimica et biophysica acta. 2014; 1846: 524-538.
24. Yu Z, Zhang W, Kone BC. Histone deacetylases augment cytokine induction of the iNOS gene. Journal of the American Society of Nephrology : JASN. 2002; 13: 2009-2017.
25. Ashburner BP, Westerheide SD, Baldwin AS, Jr. The p65 (RelA) subunit of NF-kappaB interacts with the histone deacetylase (HDAC) corepressors HDAC1 and HDAC2 to negatively regulate gene expression. Molecular and cellular biology. 2001; 21: 7065-7077.
26. Kaler P, Sasazuki T, Shirasawa S, Augenlicht L, Klampfer L. HDAC2 deficiency sensitizes colon cancer cells to TNFalpha-induced apoptosis through inhibition of NF-kappaB activity. Experimental cell research. 2008; 314: 1507-1518.
27. Ito K, Jazrawi E, Cosio B, Barnes PJ, Adcock IM. p65-activated histone acetyltransferase activity is repressed by glucocorticoids: mifepristone fails to recruit HDAC2 to the p65-HAT complex. The Journal of biological chemistry. 2001; 276: 30208-30215.
28. Johnson RF, Witzel, II, Perkins ND. p53-dependent regulation of mitochondrial energy production by the RelA subunit of NF-kappaB. Cancer research. 2011; 71: 5588-5597.
29. Cooks T, Pateras IS, Tarcic O, Solomon H, Schetter AJ, Wilder S, Lozano G, Pikarsky E, Forshew T, Rozenfeld N, Harpaz N, Itzkowitz S, Harris CC, Rotter V, Gorgoulis VG, Oren M. Mutant p53 Prolongs NF-kappaB Activation and Promotes Chronic Inflammation and Inflammation-Associated Colorectal Cancer. Cancer cell. 2013; 23: 634-646.
30. Ropero S, Ballestar E, Alaminos M, Arango D, Schwartz S, Jr., Esteller M. Transforming pathways unleashed by a HDAC2 mutation in human cancer. Oncogene. 2008; 27: 4008-4012.
31. Pommier Y, Leo E, Zhang H, Marchand C. DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chemistry & biology. 2010; 17: 421-433.
32. Yang F, Teves SS, Kemp CJ, Henikoff S. Doxorubicin, DNA torsion, and chromatin dynamics. Biochimica et biophysica acta. 2014; 1845: 84-89.
33. Rauch A, Hennig D, Schäfer C, Wirth M, Marx C, Heinzel T, Schneider G, Krämer OH. Survivin and YM155: how faithful is the liaison? Biochimica et biophysica acta. 2014; 1845: 202-220.
34. Kirch HC, Flaswinkel S, Rumpf H, Brockmann D, Esche H. Expression of human p53 requires synergistic activation of transcription from the p53 promoter by AP-1, NF-kappaB and Myc/Max. Oncogene. 1999; 18: 2728-2738.
35. Endo F, Nishizuka SS, Kume K, Ishida K, Katagiri H, Ishida K, Sato K, Iwaya T, Koeda K, Wakabayashi G. A compensatory role of NF-kappaB to p53 in response to 5-FU-based chemotherapy for gastric cancer cell lines. PloS one. 2014; 9: e90155.
36. Lehmann A, Denkert C, Budczies J, Buckendahl AC, Darb-Esfahani S, Noske A, Muller BM, Bahra M, Neuhaus P, Dietel M, Kristiansen G, Weichert W. High class I HDAC activity and expression are associated with RelA/p65 activation in pancreatic cancer in vitro and in vivo. BMC cancer. 2009; 9: 395.
37. Fritsche P, Seidler B, Schuler S, Schnieke A, Göttlicher M, Schmid RM, Saur D, Schneider G. HDAC2 mediates therapeutic resistance of pancreatic cancer cells via the BH3-only protein NOXA. Gut. 2009; 58: 1399-1409.
38. Dalmases A, Gonzalez I, Menendez S, Arpi O, Corominas JM, Servitja S, Tusquets I, Chamizo C, Rincon R, Espinosa L, Bigas A, Eroles P, Furriol J, Lluch A, Rovira A, Albanell J et al. Deficiency in p53 is required for doxorubicin induced transcriptional activation of NF-kB target genes in human breast cancer. Oncotarget. 2014; 5: 196-210.
39. Gao Z, Chiao P, Zhang X, Zhang X, Lazar MA, Seto E, Young HA, Ye J. Coactivators and corepressors of NF-kappaB in IkappaB alpha gene promoter. The Journal of biological chemistry. 2005; 280: 21091-21098.
40. Saldana-Meyer R, Recillas-Targa F. Transcriptional and epigenetic regulation of the p53 tumor suppressor gene. Epigenetics : official journal of the DNA Methylation Society. 2011; 6: 1068-1077.
41. Gareau JR, Lima CD. The SUMO pathway: emerging mechanisms that shape specificity, conjugation and recognition. Nature reviews. Molecular cell biology. 2010; 11: 861-871.
42. Chen L, Fischle W, Verdin E, Greene WC. Duration of nuclear NF-kappaB action regulated by reversible acetylation. Science. 2001; 293: 1653-1657.
43. Kiernan R, Bres V, Ng RW, Coudart MP, El Messaoudi S, Sardet C, Jin DY, Emiliani S, Benkirane M. Post-activation turn-off of NF-kappa B-dependent transcription is regulated by acetylation of p65. The Journal of biological chemistry. 2003; 278: 2758-2766.
44. Chen Y, Wang H, Yoon SO, Xu X, Hottiger MO, Svaren J, Nave KA, Kim HA, Olson EN, Lu QR. HDAC-mediated deacetylation of NF-kappaB is critical for Schwann cell myelination. Nature neuroscience. 2011; 14: 437-441.
45. Schwitalla S, Ziegler PK, Horst D, Becker V, Kerle I, Begus-Nahrmann Y, Lechel A, Rudolph KL, Langer R, Slotta-Huspenina J, Bader FG, Prazeres da Costa O, Neurath MF, Meining A, Kirchner T, Greten FR. Loss of p53 in enterocytes generates an inflammatory microenvironment enabling invasion and lymph node metastasis of carcinogen-induced colorectal tumors. Cancer cell. 2013; 23: 93-106.
46. Ellis L, Atadja PW, Johnstone RW. Epigenetics in cancer: targeting chromatin modifications. Molecular cancer therapeutics. 2009; 8: 1409-1420.
47. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, Sedivy JM, Kinzler KW, Vogelstein B. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science. 1998; 282: 1497-1501.
48. Ropero S, Fraga MF, Ballestar E, Hamelin R, Yamamoto H, Boix-Chornet M, Caballero R, Alaminos M, Setien F, Paz MF, Herranz M, Palacios J, Arango D, Orntoft TF, Aaltonen LA, Schwartz S, Jr. et al. A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition. Nature genetics. 2006; 38: 566-569.
49. Wilting RH, Yanover E, Heideman MR, Jacobs H, Horner J, van der Torre J, DePinho RA, Dannenberg JH. Overlapping functions of Hdac1 and Hdac2 in cell cycle regulation and haematopoiesis. The EMBO journal. 2010; 29: 2586-2597.
50. Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science. 2002; 296: 550-553.
51. Brostjan C, Anrather J, Csizmadia V, Natarajan G, Winkler H. Glucocorticoids inhibit E-selectin expression by targeting NF-kappaB and not ATF/c-Jun. Journal of immunology. 1997; 158: 3836-3844.
52. Bier C, Knauer SK, Klapthor A, Schweitzer A, Rekik A, Krämer OH, Marschalek R, Stauber RH. Cell-based analysis of structure-function activity of threonine aspartase 1. The Journal of biological chemistry. 2011; 286: 3007-3017.
53. Dosch T, Horn F, Schneider G, Kratzer F, Dobner T, Hauber J, Stauber RH. The adenovirus type 5 E1B-55K oncoprotein actively shuttles in virus-infected cells, whereas transport of E4orf6 is mediated by a CRM1-independent mechanism. Journal of virology. 2001; 75: 5677-5683.
54. Stauber RH, Knauer SK, Habtemichael N, Bier C, Unruhe B, Weisheit S, Spange S, Nonnenmacher F, Fetz V, Ginter T, Reichardt S, Liebmann C, Schneider G, Krämer OH. A combination of a ribonucleotide reductase inhibitor and histone deacetylase inhibitors downregulates EGFR and triggers BIM-dependent apoptosis in head and neck cancer. Oncotarget. 2012; 3: 31-43.
55. Schneider G, Saur D, Siveke JT, Fritsch R, Greten FR, Schmid RM. IKKalpha controls p52/RelB at the skp2 gene promoter to regulate G1-to S-phase progression. The EMBO journal. 2006; 25: 3801-3812.
56. Baumann S, Dostert A, Novac N, Bauer A, Schmid W, Fas SC, Krueger A, Heinzel T, Kirchhoff S, Schutz G, Krammer PH. Glucocorticoids inhibit activation-induced cell death (AICD) via direct DNA-dependent repression of the CD95 ligand gene by a glucocorticoid receptor dimer. Blood. 2005; 106: 617-625.
57. Buchwald M, Pietschmann K, Brand P, Günther A, Mahajan NP, Heinzel T, Krämer OH. SIAH ubiquitin ligases target the nonreceptor tyrosine kinase ACK1 for ubiquitinylation and proteasomal degradation. Oncogene. 2013; 32: 4913-4920.
58. Baumbusch LO, Myhre S, Langerod A, Bergamaschi A, Geisler SB, Lonning PE, Deppert W, Dornreiter I, Borresen-Dale AL. Expression of full-length p53 and its isoform Deltap53 in breast carcinomas in relation to mutation status and clinical parameters. Molecular cancer. 2006; 5: 47.